Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explains the remaining issues at play slowing down biosimilar uptake in the United States.
Payers have long maintained that the high cost of biologics relative to small-molecule drugs is unsustainable and a threat to their business model. However, a new analysis shows that many plans aren’t yet sold on giving less expensive biosimilars better footing on formularies compared to reference products.
Dan Danielson, RPh, MS, is the senior director, market access solutions, at PrecisionValue, a market access marketing firm.
According to an analysis of more than 1,100 coverage decisions made by 17 commercial health plans involving 19 biosimilars, insurers and pharmacy benefit managers (PBMs) are slow-walking the uptake of biosimilars by continuing to offer preferential formulary placement to the original biologics in some circumstances and parity placement for most.
So, why would a payer prefer a more expensive reference brand?
The analysis offers a clearer understanding of how discounts and rebates attached to reference products can make it more profitable for some in the value chain to obstruct the building of a vibrant biosimilars market in the United States.
It found that payers are often less likely to prefer biosimilars or place them at parity. This is particularly true if the biosimilar in question has a pediatric indication or is for a condition with at least 1 million prevalent cases.
The analysis showed a reticence for payers to promote access to biosimilars unless:
Another determining factor in the economics of biosimilars coverage concerns wholesale acquisition cost (WAC). Price-sensitive plans such as Medicare, Medicaid, Veterans Affairs and nonprofit coverage networks often prefer the up-front discounts provided through low-WAC products. On the other hand, PBMs and rebate-sensitive plans—which may have rebate guarantees with downstream clients—prefer high-WAC products and the higher rebates they generate.
The role of PBMs and rebate incentives stood out as the biggest determining factor in the decision to deploy step therapy and other utilization management practices to slow biosimilars uptake. Plans aligned with one of the “big 3” PBMs (CVS Caremark, Express Scripts, and Optum Rx) often are not able to alter formulary content or customize as the so-called national formularies seek to pull in as many rebates as possible across all therapy areas. PBMs generally favor accumulating rebates on the original biologic unless the cost of the branded product cannot be rebated down to less than that of the biosimilar.
It bears noting that even if plans and PBMs begin to provide on par or better formulary placement for biosimilars, that access will only be as helpful as the efforts made to educate providers about the availability and efficacy of biosimilar alternatives. This “pull through” is critical. After all, biosimilars are competing brands, and prescribers cannot write for them if they don’t know their names. Also, prescribers are creatures of habit who need to become comfortable with a particular biosimilar, suggesting the need for provider-facing campaigns by manufacturers to keep biosimilars top of mind. Finally, pharmacists cannot substitute most reference products with less expensive biosimilars.
When Hatch-Waxman was passed in 1984, creating the generics market for small-molecule drugs, we saw a corollary to some of the challenges facing our nascent biosimilars market today in terms of gaining trust and acceptance of less expensive alternatives. Forty years later, the main difference is how rebate incentives have changed the marketplace and heavily influenced the coverage calculus of both drugs covered by pharmacy benefits that are processed by PBMs as well as medical benefits.
For the United States to catch up to Europe on biosimilar uptake, payers need to examine rebate guarantees and make sure that they don't favor long-term disincentives to cost savings due to the short-term needs of a particular client. Biosimilar manufacturers will need to examine how they are educating providers about the safety, efficacy and savings provided by biosimilar products.
Reference
Yu T, Jin S, Li C, Chambers JD, Hlávka JP. Factors associated with biosimilar exclusions and step therapy restrictions among US commercial health plans. BioDrugs. 2023;37(4):531-540. doi:10.1007/s40259-023-00593-7
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.